Catalyst Oncology, the biotech-focused oncology CRO brand of Catalyst Clinical Research, has announced a collaboration with Imerman Angels, a nonprofit organization providing free, personalized one-on-one cancer support.
 
Catalyst Oncology’s goal is to increase the visibility of the support and resources Imerman Angels makes available to cancer patients, survivors, and caregivers to ensure no one faces cancer alone.
 
“Catalyst is excited to collaborate with Imerman Angels, an organization that shares our dedication to improving the lives of those affected by cancer,” said Keya Watkins, Senior Vice President, Catalyst Oncology. “This connection is a great reminder that we are part of a larger community that can make an impressive impact alongside Imerman Angels, which provides comprehensive support to patients and their families. This also reinforces Catalyst Oncology’s commitment to help our innovative biotech clients develop therapies to support cancer patients.”
 
“We are looking forward to working with Catalyst Oncology,” said Jonny Imerman, Co-founder and Chief Mission Officer, Imerman Angels. “Together, we can reach more individuals, provide more support, and make a greater impact in the cancer community.”
 
The collaboration will kick off with a private event on National Cancer Survivors Day, a day dedicated to honoring and celebrating cancer survivors, their families, and caregivers, which occurs during the American Society of Clinical Oncology (ASCO) annual conference in Chicago.